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Abstract: For more than ten years, new synthetic cathinones (SCs) mimicking the effects of controlled
cocaine-like stimulants have flooded the illegal drug market, causing numerous intoxications and
fatalities. There are often no data on the pharmacokinetics of these substances when they first
emerge onto the market. However, the detection of SC metabolites is often critical in order to
prove consumption in clinical and forensic settings. In this research, the metabolite profile of two
pyrrolidinyl SCs, α-pyrrolidinohexaphenone (α-PHP) and 400 -fluoro-α-pyrrolidinovalerophenone
(4F-α-PVP), were characterized to identify optimal intake markers. Experiments were conducted
using pooled human hepatocyte incubations followed by liquid chromatography–high-resolution
tandem mass spectrometry and data-mining software. We suggest α-PHP dihydroxy-pyrrolidinyl,
α-PHP hexanol, α-PHP 20 -keto-pyrrolidinyl-hexanol, and α-PHP 20 -keto-pyrrolidinyl as markers of
α-PHP use, and 4F-α-PVP dihydroxy-pyrrolidinyl, 4F-α-PVP hexanol, 4F-α-PVP 20 -keto-pyrrolidinylhexanol, and 4F-α-PVP 20 -keto-pyrrolidinyl as markers of 4F-α-PVP use. These results represent the
first data available on 4F-α-PVP metabolism. The metabolic fate of α-PHP was previously studied
using human liver microsomes and urine samples from α-PHP users. We identified an additional
major metabolite (α-PHP dihydroxy-pyrrolidinyl) that might be crucial for documenting exposure
to α-PHP. Further experiments with suitable analytical standards, which are yet to be synthesized,
and authentic specimens should be conducted to confirm these results.
Keywords: α-PHP; PV7; 4F-α-PVP; novel psychoactive substance; synthetic cathinone; bath salt;
hepatocyte metabolism; liquid chromatography–high resolution tandem mass spectrometry
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1. Introduction
Synthetic cathinones (SCs), or bath salts, are novel psychoactive substances (NPSs)
designed to induce cocaine-like stimulant effects while evading legislation and analytical
detection. SCs inhibit the transport of monoamines in the central nervous system, with
specific affinities for dopamine, norepinephrine, and serotonin transporters (DAT, NET,
and SERT, respectively), inducing euphoria and increased energy, but also tachycardia,
elevated blood pressure, hyperthermia, agitation, delirium, psychosis, and death. SC
use accounts for many intoxications and deaths, mainly through cardiac arrest or multiorgan failure [1,2]. SC effects are closely related to their specific selectivity for DAT, NET,
and SERT. Particularly, DAT/SERT inhibition is associated with distinct psychoactive
effects and abuse liability. For example, methedrone and 4-ethylmethcathinone have
DAT/SERT inhibition ratios similar to that of 300 ,400 -methylenedioxymethamphetamine
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(MDMA), whereas methylenedioxypyrovalerone (MDPV) and pyrovalerone have a much
higher ratio, resulting in higher reinforcing effects and abuse potential [3].
α-PHP (or PV7 or α-pyrrolidinohexaphenone, 1-phenyl-2-(10 -pyrrolidinyl)-1-hexanone)
and 4F-α-PVP (or 400 -fluoro-α-pyrrolidinovalerophenone, 1-(400 -fluorophenyl)-2-(10 pyrrolidinyl)-1-pentanone) are pyrrolidinyl SCs, characterized by the presence of a butyl
chain and a phenyl for α-PHP, and a propyl chain and a para-fluoro-phenyl ring for 4F-αPVP (Figure 1). Both SCs were first identified in 2014 in material seized in the Japanese
illegal drug market or for sale over the Internet [4,5]. α-PHP was recently involved in
several combined drug intoxication fatalities [6–10]. All the cases involved the co-ingestion
of other SCs, mainly α-pyrrolidinovalerophenone (α-PVP) and 300 ,400 -methylenedioxy-αpyrrolidinohexiophenone (MDPHP), or often opiates and/or benzodiazepines. A total
of 13 α-PHP-related deaths were reported to the early warning system of the European
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) between 2017 and 2020 [2],
with additional cases reported to the United Nations Office on Drugs and Crime (UNODC)
early warning advisory system [11]. No intoxication cases or deaths involving 4F-α-PVP
have been reported to date. Halogenated SCs inhibit SERT with a higher potency than
that of their non-halogenated analogues, inducing potentially fatal serotonin syndrome
effects—tachycardia; nausea; hyperthermia; rhabdomyolysis; psychomotor tremors; and
liver, kidney, and lung failure [12–15]. Therefore, 4F-α-PVP is expected to demonstrate
higher toxicity than α-PVP, which has been involved in many intoxications and fatalities [1,2]. Halogenated SC use recently became popular, likely due to its higher potency [2],
and 4F-α-PVP use is also expected to increase. In December 2019, the World Health Organization (WHO) recommended the control of α-PHP under Schedule II of the UNODC
convention on psychotropic substances of 1971 [16]. It is currently controlled under Class B
in the United Kingdom; Schedule I in the United States; is illegal in China, Sweden, Poland,
and Italy; and is classified as a narcotic in Japan [11,17]. 4F-α-PVP is illegal in China and
classified as a designated chemical substance in Japan [17].

Figure 1. Chemical structures of α-PHP, 4F-α-PVP, and structural analogues α-PPP, α-PBP, α-PVP,
4-MeO-α-PVP, PV8, and PV9.

Exposure to α-PHP can be determined through the detection of parent drugs in biological specimens [6–9]. α-PHP has been quantified in post-mortem cases with concentrations
ranging from 4 to 52 ng/mL in blood [6,7], 5.6 ng/mL in urine [9], 3.5 to 83.3 ng/g in tis-
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sues [9], and 4700 pg/mg in hair [8]. Although α-PHP was not the primary cause of death in
these cases, active and toxic concentrations are expected to be low. 4F-α-PVP concentrations
in biological specimens have not been reported to date. In clinical and forensic settings,
toxicologists often focus on the detection of drug metabolites in urine, which are often
detected in higher concentrations and over an extended time course. A prerequisite for the
detection of metabolites is the characterization of the drug’s metabolic fate. However, there
are often no data on SC pharmacokinetics when they first emerge onto the illegal drug market. To date, there are no data available on 4F-α-PVP pharmacokinetics. α-PHP metabolism,
however, was investigated using human liver microsomes and authentic urine samples.
Several α-PHP metabolites were identified, mainly involving ketoreduction, pyrrolidinyl
oxidation, and N-dealkylation to N-butanoic acid or N-hydroxy-40 -ketobutyl [18]. Reduction of the ketone group is a prominent transformation in SC metabolism [19–23], but it is
not detected in human liver microsomes and human S9 fractions [24–26]. In vitro incubations with human hepatocytes have proved suitable for the prediction of NPS metabolic
fate in previous studies [27–34]. Additionally, it has proven particularly accurate for the
prediction of urinary metabolites of structural analogues α-pyrrolidinoheptaphenone (PV8)
and α-pyrrolidinopentiothiophenone (α-PVT) (Figure 1), suggesting an important hepatic
metabolism of pyrrolidinyl SCs [21,22]. Combining human hepatocyte incubations and
the analysis of urine samples from authentic users seems therefore the best strategy to
identify optimal SC use markers. Considering the potential health threat of α-PHP and
4F-α-PVP, we investigated their metabolite fate using pooled human hepatocyte incubations, liquid chromatography–high-resolution tandem mass spectrometry (LC-HRMS/MS),
and data-mining software, with the aim of identifying suitable markers of consumption.
2. Results and Discussion
2.1. α-PHP and 4F-α-PVP MS/MS Fragmentation Patterns
As expected from two structural analogues, α-PHP and 4F-α-PVP display similar
fragmentation patterns (Figures 2 and 3). Major fragments are produced through C-C
cleavage at the α carbons of the carbonyl and pyrrolidinyl groups, yielding fragments m/z
105.0334 and 140.1432 from α-PHP, and m/z 123.0241 and 126.1277 from 4F-α-PVP. Further
fragmentation and rearrangement yield the characteristic tropylium ion from α-PHP (m/z
91.0542), the fluorotropylium ion from 4F-α-PVP (m/z 109.0448), and the pyridinium
ion from both molecules (m/z 84.0808). C-C cleavage at the pyrrolidinyl α carbon also
produces fragments m/z 175.1117 and 189.1147 for α-PHP, m/z 179.0867 and 207.1052
for 4F-α-PVP, and m/z 72.0808 for both. Further fragmentation produces fragments m/z
119.0491 and 137.0397 from fragments m/z 175.1117 and 179.0867, respectively. McLafferty
rearrangement through the ionization of the oxygen atom may occur, yielding fragment
m/z 70.0652 from α-PHP and 4F-α-PVP. α-PHP fragmentation matches well with that
reported by Matsuta et al., although the instrument employed was different [35]. 4F-α-PVP
MS/MS fragmentation was described by Uchiyama et al. by gas chromatography (GC)-MS,
but the authors only identified two fragments, i.e., m/z 95 (attributed to the fluorophenyl
group) and 126 [5].
2.2. α-PHP Metabolism with Human Hepatocytes
The α-PHP signal decreased to 21% after 3 h incubation with hepatocytes, generating
a total of 24 metabolites. Five metabolites totaling more than 95% of the total metabolite
peak area are described in this article are listed from P1 to P5 by ascending retention
time (Figure 4). All metabolites were absent from controls, ruling out interferences and
non-enzymatic reactions.
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Figure 2. Product ion spectra of α-PHP (a1) and metabolites P1 (b1), P2 (c1), P3 (d1), P4 (e1), and P5 (f1), and their
postulated fragmentation patterns (a2–f2, respectively). Dashed arrow indicates fragmentation site.
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Figure 3. Product ion spectra of 4F-α-PVP (a1) and metabolites F1 (b1), F2 (c1), F3 (d1), F4 (e1), and F5 (f1), and their
postulated fragmentation patterns (a2–f2, respectively). Dashed arrow indicates fragmentation site.
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Figure 4. Combined extracted ion chromatogram of α-PHP (a), 4F-α-PVP (b), and metabolites obtained from 3 h hepatocyte
incubation. Mass tolerance, 5 ppm; RT, retention time.

Major metabolic reactions included reduction of the ketone group (P3 and P4) and
hydroxylation (P1 and P2) and oxidation (P4 and P5) of the pyrrolidinyl ring. Dealkylation
to the primary amine and alkyl hydroxylation were identified as minor phase I metabolites.
α-PHP alkyl chain transformations were less frequent than those of structural analogues
with a longer chain [20,21]. However, Manier et al. reported that α-PHP was mainly
hydroxylated at the pyrrolidinyl ring [26], in accordance with our results. In fact, the length
of the alkyl chain seems to strongly influence the metabolic pathway of analogues [35].
Phase II glucuronidations were also rare, as observed in the metabolic profile of analogues
(in vitro and in vivo) [21,22] and that of α-PHP in the urine of several users [18]. Therefore,
hydrolysis may be not a prerequisite for the detection of α-PHP and metabolites in urine.
The accurate mass molecular ion, retention time, elemental composition, nominal mass for
diagnostic product ions, and mass spectrometry peak areas (extracted ion chromatogram)
for P1–P5 are reported in Table 1. The fragmentation pattern of P1–P5 is displayed in
Figure 2. α-PHP’s metabolic pathway is proposed in Figure 5.
2.2.1. β-Ketoreduction
Reduction of the α-PHP ketone group (+2H) resulted in the formation of P3 (α-PHP
hexanol), as suggested by a +2.0157 Da mass shift from parent and a water loss (m/z
230.1899) detected in P3’s product-ion spectrum. The signal intensity of the water loss was
particularly intense, as it is favored by the proximity of the phenyl group. The low intensity
of ion m/z 70.0652 compared to m/z 72.0807), and the absence of ion m/z 177.1274 (m/z
175.1117 in α-PHP) suggested that McLafferty rearrangement did not occur, due to the
reduction of the ketone group. Instead, ion m/z 173.1198, produced by C-C cleavage at
the α carbon of the pyrrolidinyl group and a water loss, was intense. The presence of the
tropylium ion further indicated that the phenyl group did not carry the transformation.
β-ketoreduction is a prominent transformation in SC metabolism [19–23], and P3 was
indeed one of the metabolites with the most intense signal in our experiments. It was also
detected as a major metabolite by Paul et al. and Matsuta et al. in urine samples from
α-PHP users [18,35].
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Table 1. Accurate mass molecular ion, retention time (RT), elemental composition, nominal mass for diagnostic product ions, MS peak areas, and α-PHP and 4F-α-PVP metabolites peak
area fraction (sum = 95 and 98%, respectively) in hepatocyte incubations. Peak area for α-PHP and 4F-α-PVP at T0h were 6.1 × 107 and 7.5 × 107 , respectively. Metabolites are listed by
ascending RT. MS, mass spectrometry; ND, not detected.
ID

Biotransformation

α-PHP

Parent drug
Hydroxylation
(α-PHP
20 -hydroxypyrrolidinyl)
Dihydroxylation
(α-PHP
dihydroxy-pyrrolidinyl)
β-Ketoreduction
(α-PHP hexanol)
β-Ketoreduction + Ketone
formation
(α-PHP
20 -ketopyrrolidinyl-hexanol)
Ketone formation
(α-PHP 20 -ketopyrrolidinyl)
Parent drug
Hydroxylation
(4F-α-PVP
20 -hydroxypyrrolidinyl)
Dihydroxylation
(4F-α-PVP
dihydroxy-pyrrolidinyl)
β-Ketoreduction
(4F-α-PVP hexanol)
β-Ketoreduction + Ketone
formation
(4F-α-PVP
20 -ketopyrrolidinyl-hexanol)
Ketone formation
(4F-α-PVP
20 -ketopyrrolidinyl)

P1

P2
P3

P4

P5
4F-α-PVP
F1

F2
F3

F4

F5

[M + H]+
(m/z)

RT (min)

Mass Error (ppm)

Elemental
Composition

Diagnostic Product Ions
(m/z)

Peak Area at T3h

246.1848

9.38

1.79

C16 H23 NO

70, 91, 105, 119, 140, 175

1.3 × 107

262.1798

8.70

1.32

C16 H23 NO2

70, 91, 105, 119, 156, 175

6.1 × 105

2.6%

278.1746

9.02

1.72

C16 H23 NO3

87, 91, 105, 118, 174, 186

1.0 × 107

44%

248.2005

9.66

1.63

C16 H25 NO

72, 91, 104, 117, 173, 230

9.7 × 106

40%

262.1799

12.52

0.97

C16 H23 NO2

70, 86, 91, 98, 117, 159

1.3 × 106

5.3%

260.1642

14.77

1.00

C16 H21 NO2

86, 91, 105, 129, 133, 175

7.0 × 105

2.9%

107

Metabolites Peak
Area Fraction (%)

250.1598

8.71

1.33

C15 H20 FNO

70, 84, 109, 123, 126, 179

2.2 ×

266.1547

8.12

1.35

C15 H20 FNO2

70, 109, 123, 142, 179, 248

6.4 × 105

2.8%

282.1496

8.46

1.42

C15 H20 FNO3

87, 109, 123, 136, 178, 179

9.4 × 106

41%

252.1755

8.94

1.18

C15 H22 FNO

72, 109, 122, 190, 191, 234

9.1 × 106

40%

266.1548

11.70

1.01

C15 H20 FNO2

86, 98, 109, 135, 163, 248

1.7 × 106

7.4%

264.1391

14.00

1.15

C15 H18 FNO2

98, 109, 123, 140, 161, 179

1.6 × 106

7.1%
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Figure 5. Postulated metabolic pathway of α-PHP and 4F-α-PVP. Double arrow indicates major pathway.

Reduction of the ketone group implies the formation of a chiral center and two
diastereoisomers, depending on hydroxyl positioning. Matsuta et al. determined that the
formation of one isomer is favored over the other (ten-times higher concentration), but they
could not distinguish the two molecules [35]. Most probably, the two metabolites coeluted
in our experiments, which is not problematic considering that HRMS/MS is not suitable to
identify the two isomers.
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2.2.2. Pyrrolidinyl Hydroxylation
P1 (α-PHP 20 -hydroxy-pyrrolidinyl) was formed by hydroxylation (+O), as suggested
by a +15.9950 Da mass shift from the parents and a water loss (m/z 244.1693) detected after
fragmentation. The presence of ions m/z 91.0542, 105.0335, and 175.1117, also detected
in the α-PHP product-ion spectrum, indicated that the transformation occurred at the
pyrrolidinyl ring. Ion m/z 156.1382 (m/z 140.1432 in α-PHP) also suggested that the
hydroxylation occurred either at the pyrrolidinyl ring or the alkyl chain of the molecule.
The exact position of the hydroxylation could not be determined. However, the metabolic
profile of structural analogues α-PVP and α-PBP strongly suggests that the hydroxylation
may have occurred at position 20 of the pyrrolidinyl ring, forming a hemiaminal group that
can be an intermediate to P4 and P5 (Section 2.2.3.) [36–38].
P2 (α-PHP dihydroxy-pyrrolidinyl) was the metabolite with the most intense signal
detected in our experiments. The +31.9898 Da mass shift from α-PHP and the two water losses (m/z 260.1643 and 242.1535) suggested a dihydroxylation (+2O). Like P1, ions
m/z 91.0541, 105.0334, and 175.1117 indicated that the transformations occurred at the
pyrrolidinyl ring. Pyrrolidinyl dihydroxylation was also a major transformation in the
metabolic pathway of 4-methoxy-α-PVP and α-PVT, two structural analogues, using human hepatocytes and urine samples from users [22,23]. P2’s molecular mass and theoretical
formula also match those of α-PHP N-butanoic acid, which could theoretically be formed
by γ-lactam formation, then N-dealkylation and further carboxylation of the pyrrolidinyl
ring, as reported in the metabolism of SCs with an analogous structure [26]. However, the
absence of carboxylic acid loss and the presence of two water losses in the P2 fragmentation
pattern rather indicate a dihydroxylation. Additionally, Vickers and Polsky determined
that further transformation following lactam formation (Section 2.2.3.) is unlikely in the
metabolism of N-heterocycles [36]. Lactam opening was observed in the metabolism of
nicotine, an extensively studied molecule with a pyrrolidinyl substructure, but it was
only a minor metabolic pathway [39]. Paul et al. identified two major α-PHP metabolites
with P2 molecular mass in the urine of an authentic user, which they attributed to the
formation of N-butanoic acid and N-hydroxy-40 -oxobutane (M13 or M14, respectively,
in the article), both formed by lactam formation and opening of the N-heterocycle [18].
They correctly located the position of the transformations on the pyrrolidinyl ring of the
molecule (fragments m/z 91.0542 and 175.1117). Like P2 in our experiments, the authors
did not detect a carboxylic acid loss in the M13 and M14 fragmentation patterns, but they
detected one (M13) or two (M14) water losses instead. They also detected further minor
metabolites with subsequent hydroxylation and dealkylation. We believe that these data
rather point towards two different dihydroxylations at the pyrrolidinyl ring, as identified
in the present study (P2). Comparison with suitable analytical standards, which are yet
to be synthesized, would bring a definite answer. In another article, Matsuta et al. did
not identify P1 and P2 during their investigation of α-PHP metabolism using the urine of
five authentic users, as they mainly focused on the metabolic transformations at the alkyl
chain [35]. The characterization of P2, a potential major metabolite that was not reported in
previous studies, might be crucial for documenting α-PHP use.
Manier et al. determined the kinetics of α-PHP hydroxylations using human liver
microsomes and S9 human fractions [26]. They determined that cytochrome P450 (CYP) 2C9
is mainly involved in the hydroxylation of α-PHP (71% of reactions with selected enzymes);
CYP2C19, CYP3A4, and CYP2B6 catalyzed 18%, 6%, and 5% of reactions, respectively.
2.2.3. Oxidation
Pyrrolidinyl oxidation or hydroxylation and dehydrogenation (+O –2H) occurred in
P5 (α-PHP 20 -keto-pyrrolidinyl), as indicated by a +13.9794 Da mass shift from the parents
and the detection of α-PHP fragments m/z 91.0542, 105.0335, and 175.1117. P5’s late elution
compared to parents supported an oxidation at position 20 of the pyrrolidinyl ring (γlactam), which acts as a hindrance for hydrogen bonding [22]. In addition, 20 -pyrrolidinyl
oxidation is another transformation that is predominant in the metabolism pyrrolidinyl-
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containing molecules through CYP metabolism [36] and pyrrolidinyl SCs [19–24,26], and it
was also detected as a major metabolite by Paul et al. and Matsuta et al. in urine samples
from α-PHP users [18,35]. Fragment m/z 86.0600 may also be explained by another
McLafferty rearrangement through the ionization of the newly formed amide group.
Following the same reasoning, we found that P4 (α-PHP 20 -keto-pyrrolidinyl-hexanol)
was formed by oxidation at the pyrrolidinyl ring (+O –2H), as observed in P5, and a
β-ketoreduction (+2H), as observed in P3 (Section 2.2.1.).
2.3. 4F-α-PVP Metabolism with Human Hepatocytes
The 4F-α-PVP signal decreased to 29% after 3 h incubation with human hepatocytes.
A total of 11 metabolites were identified, with five molecules totaling more than 97% of the
total metabolite peak area, which were listed from F1 to F5 by ascending retention time
(Figure 4). All metabolites were absent in controls.
4F-α-PVP’s major transformations were the same as those of α-PHP, with similar
relative intensities (Table 1). Fewer minor metabolic reactions were detected, and no transformations of the alkyl chain were identified, in consistency with the results of Matsuta
et al. on the influence of the alkyl chain length on the metabolic profile of analogues [35].
Several alkyl chain transformations, however, were observed in α-PVP metabolism using human hepatic microsomes and controlled administrations to rats [24]. No phase II
transformations were detected either. The fragmentation pattern of F1–F5 is displayed in
Figure 3. 4F-α-PVP’s metabolic pathway is proposed in Figure 5.
2.3.1. β-Ketoreduction
Unsurprisingly, β-ketoreduction (+2H) appeared as a major metabolic transformation
in our experiments, leading to F3 formation (4F-α-PVP hexanol). F3 fragmentation and
fragment relative intensities were very similar to those of P3 (Section 2.2.1.), with fragment
mass shifts depending on the fluorine atom and the alkyl side chain. Like α-PHP, mass
shift from parent (+2.0157 Da), and ions m/z 72.0808, 109.0448, 191.1104, and 234.1651
allowed for F3 identification. β-ketoreduction is also a major metabolic transformation of
α-PHP (Section 2.2.1.) and other SCs such as α-PBP, α-PVP, and α-PVT [19–23].
2.3.2. Pyrrolidinyl Hydroxylation
Pyrrolidinyl hydroxylation (+O) also occurred in 4F-α-PVP, producing F1 (4F-α-PVP
20 -hydroxy-pyrrolidinyl). Like F3, F1’s fragmentation pattern and fragment relative intensities
were similar to those of P1 (Section 2.2.2.). The mass shift from parents (+15.9949 Da) and
ions m/z 109.0447, 123.0239, 142.1225, 179.0865, and 248.1442 indicated a hydroxylation at
the pyrrolidinyl ring. As suggested by the metabolic profile of structural analogues α-PVP
and α-PBP, the reaction probably occurred at position 20 of the pyrrolidinyl ring, forming a
hemiaminal group that can be an intermediate for F4 and F5 formation (Section 2.3.3.) [37,38].
Like α-PHP and other SCs [22,23], pyrrolidinyl dihydroxylation (+2O) was a major
4F-α-PVP metabolic transformation. F2 (4F-α-PVP dihydroxy-pyrrolidinyl) was identified
through the +31.9898 Da mass shift from the parents and ions m/z 109.0447, 123.0240,
and 179.0867, similar to α-PHP (Section 2.2.2.). Although the opening and carboxylation
of the pyrrolidinyl ring was observed in the metabolism of several SCs with a similar
structure [26], the absence of carboxylic acid and the presence of two water losses (m/z
264.1391 and 246.1289) in the F2 fragmentation pattern indicated a dihydroxylation.
2.3.3. Oxidation
Another frequent metabolic transformation of pyrrolidinyl SCs is the formation of
a γ-lactam [19–24,26]. The F5 (4F-α-PVP 20 -keto-pyrrolidinyl) retention time shift and
the +13.9793 Da mass shift from 4F-α-PVP, and ions m/z 109.0448, 123.0240, and 179.0866
indicated a formation of a ketone at position 20 of the pyrrolidinyl ring, similar to α-PHP
(Section 2.2.3.).
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F4 (4F-α-PVP 20 keto-pyrrolidinyl-hexanol) was a combination of β-ketoreduction
(+2H) and pyrrolidinyl oxidation (+O –2H).
2.4. Optimal Targets for α-PHP and 4F-α-PVP
The four α-PHP metabolites with the most intense signal intensity detected after
3 h incubation with human hepatocytes were α-PHP dihydroxy-pyrrolidinyl (P2), α-PHP
hexanol (P3), α-PHP 20 -keto-pyrrolidinyl-hexanol (P4), and α-PHP 20 -keto-pyrrolidinyl (P5),
with P2 and P3 representing almost 85% of the total metabolite peak area. Similarly, the four
4F-α-PVP metabolites with the most intense signal intensity were 4F-α-PVP dihydroxypyrrolidinyl (F2), 4F-α-PVP hexanol (F3), 4F-α-PVP 20 -keto-pyrrolidinyl-hexanol (F4),
and 4F-α-PVP 20 -keto-pyrrolidinyl (F5), with F2 and F3 representing more than 80% of the
total metabolite peak area. To the best of the authors’ knowledge, these metabolites were
not observed in the metabolism of other SCs and can be used as targets for α-PHP and
4F-α-PVP use. α-PiHP is an α-PHP isomer with a 4-methyl-pentanone structure instead
of a hexanone, which was recently identified in seized materials [40]. α-PiHP possesses
the same molecular formula and mass as those of α-PHP and the identification of the two
SCs could be problematic. Although the metabolic fate of α-PiHP has not yet been studied,
the alkyl chain of α-PHP major metabolites remained untransformed, and it is unlikely to
observe P2, P3, P4, or P5 in α-PiHP metabolism. Similarly, α-PHP major metabolites are
unlikely to be found in the metabolism of pyrovalerone, another isomer [41].
Glucuronide and sulfate hydrolysis are not required for PHP and 4F-α-PVP urinalysis
due to the low incidence of phase II transformations.
2.5. Analytical Considerations
GC separation should be avoided for SC testing and metabolite identification, considering their thermal degradation through oxidative decomposition [42]. This decomposition
was also observed with α-PVP, most likely resulting in formation of an enamine [43]. Although derivatization can increase SC thermal stability, pyrrolidinyl SCs are not derivatized
with common reagents, and the derivatization of metabolites is not guaranteed [42]. Additionally, small molecules and metabolites may be unstable at high temperatures during
derivatization or GC testing [44]. LC-MS/MS is typically used for metabolite identification
studies, and HRMS is popular for identifying expected and unexpected metabolites with
accurate-mass capabilities. We employed a long chromatographic run to best separate
isomers and limit matrix effects. We selected a polar end-capped C18 column and a mobile
phase gradient, as previously reported in other SC metabolite identification studies [21–23].
The lack of a buffer limited interference and ammonium, sodium, and potassium adducts.
Metabolites are generally more polar than parent drugs to favor elimination. However, SC
metabolites with γ-lactam formation often appeared to elute later than parents in reversedphase chromatography [18,21–23,35]. Therefore, we ensured that αPHP and 4F-α-PVP
approximately eluted mid-gradient to best separate the metabolites.
MS source parameters were optimized using α-PHP and 4F-α-PVP reference standards
in an attempt to achieve good signals. However, the behavior of metabolites in these
conditions is hardly predictable. Similarly, a ramped collision energy generated many
specific fragments to allow metabolite identification, but optimal collision energy may
differ from one metabolite to another. Two different injections with a different acquisition
mode maximized the fragmentation of metabolites (Section 3.4.2.). Data-dependent MS/MS
acquisition with dynamic exclusion and apex triggering enabled us to obtain a few MS/MS
spectra for each chromatographic peak and allowed molecules with a less intense signal
intensity to also trigger MS/MS spectra.
3. Material and Methods
3.1. Chemicals and Reagents
α-PHP (1-phenyl-2-(10 -pyrrolidinyl)-1-hexanone) and 4F-α-PVP (1-(400 -fluorophenyl)standards were purchased from Cayman Chemical (Ann

2-(10 -pyrrolidinyl)-1-pentanone)
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Arbor, MI, USA), and diclofenac standard was acquired from Toronto Research Chemicals
(Toronto, ON, Canada). All the standards were dissolved in methanol to 1 mg/mL and
stored at −20 ◦ C until analysis. Water, formic acid, and methanol (Optima™ LC/MS)
were from Fisher Scientific (Fair Lawn, NJ, USA), and acetonitrile was obtained from
Sigma-Aldrich® (St. Louis, MO, USA). All the solvents and reagents were LC-MS grade.
Ten-donor-pooled cryopreserved human hepatocytes and Krebs–Henseleit buffer (KHB)
were purchased from BioreclamationIVT (Baltimore, MD, USA).
3.2. Incubation with Pooled Human Hepatocytes
Incubations with human hepatocytes were conducted following our on-site workflow,
as previously described [45,46]. Briefly, the hepatocytes were thawed at 37 ◦ C and solubilized in KHB to 2 × 106 viable cells/mL. Two hundred fifty microliters cell suspension
was gently mixed with 250 µL of 20 µmol/L α-PHP or 4F-α-PVP in KHB and incubated
at 37 ◦ C for 0 or 3 h. Reactions were quenched with 500 µL acetonitrile and incubates
were stored at −80 ◦ C until analysis. Diclofenac was incubated under the same conditions
to ensure proper metabolic activity. Negative controls with α-PHP or 4F-α-PVP in KHB
without hepatocytes, and with KHB and hepatocytes without the drugs were incubated
simultaneously. Each incubation was performed once due to the high cost of pooled human
hepatocytes, but positive and negative controls were included to document appropriate
metabolic activity and control for potential interference and contribution from the blank.
The advantages and limitations of this approach are further discussed in two recent review
articles [47,48].
3.3. Sample Preparation
Incubates were thawed at room temperature and vortex mixed. One hundred microliters was vortex mixed with 100 µL acetonitrile and centrifuged at 4 ◦ C, 15,000× g,
for 10 min. Supernatants were evaporated to dryness at 40 ◦ C, and the residues were
reconstituted in 150 µL LC mobile phases A:B 80:20 (v/v). After centrifugation at 4 ◦ C,
15,000× g, for 5 min, supernatants were transferred into LC autosampler vials with glass
inserts.
3.4. LC-HRMS/MS Parameters
LC-HRMS/MS analysis was performed on a Dionex Ultimate™ 3000 chromatography
system coupled with a Thermo Scientific Q Exactive™ (Fremont, CA, USA) Plus mass
spectrometer with a heated electrospray ionization (ESI) interface operating in positive-ion
mode. During method optimization, α-PHP and 4F-α-PVP did not produce any signal
when ESI was operated in negative-ion mode, and their metabolites were likely to produce
a signal in positive-ion mode. Data reprocessing was performed in Ancona, Italy, on a
Dionex Ultimate™ 3000 coupled with a Q Exactive™ (Ancona, Italy) combined with heated
ESI operating in the same conditions.
3.4.1. LC Parameters
Samples were kept at 15 ◦ C in an autosampler and 15 µL was injected onto the
chromatographic system. Separation was achieved on a Synergi™ Hydro-RP column
(100 × 2.0 mm, 4.0 µm; Phenomenex, Torrance, CA, USA) equipped with a guard cartridge
of identical stationary phase (10 × 2.1 mm; Phenomenex) that was maintained at 30 ◦ C
throughout the analysis. A 30 min elution was performed with 0.1% formic acid in water
(mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B) at a 0.4 mL/min
flow rate—the gradient started with 2% B held for 2 min, was increased to 95% B within
18 min, and was held at 95% B for 5 min, before returning to initial conditions within 1 min,
followed by a 4-min equilibration. LC efflux was diverted to waste the first 2 min and the
last 5 min of the gradient.
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3.4.2. HRMS/MS Parameters
Source parameters were optimized by post-column infusion of α-PHP and 4F-α-PVP
standards in LC mobile phases A:B 50:50 (v/v) at 0.5 mL/min. Source parameters for
α-PHP incubates were: spray voltage, 4 kV; sheath gas flow rate, 50 arbitrary units (a.u.);
auxiliary gas flow rate, 5 a.u.; sweep gas flow rate, 2 a.u.; S-lens radio frequency level,
50 a.u.; auxiliary gas heater temperature, 400 ◦ C; capillary temperature, 300 ◦ C. Source
parameters for 4F-α-PVP incubates were: spray voltage, 4 kV; sheath gas flow rate, 40 a.u.;
auxiliary gas flow rate, 5 a.u.; sweep gas flow rate, 2 a.u.; S-lens radio frequency level,
50 a.u.; auxiliary gas heater temperature, 500 ◦ C; capillary temperature, 300 ◦ C. Injections
were performed in duplicate with two different acquisition modes to obtain orthogonal
spectral information.
In a first injection, data were acquired in full-scan MS (FullMS) and data-dependent
MS/MS (ddMS2 ) modes, which triggered MS/MS data acquisitions based on the intensity
of the ions detected in FullMS scans and an inclusion list of expected metabolites. FullMS
settings were: resolution, 70,000; scan time, 2–25 min; mass range, m/z 100–500; automatic
gain control (AGC) target, 1 × 106 ; max injection time (IT), 200 ms. ddMS2 settings were:
resolution, 17,500; topN, 5 (pick others if idle); intensity threshold, 2 × 104 ; isolation
window, m/z 1.5; normalized collision energy (NCE), 40%, 50%, and 60% (35%, 50%,
and 65% for 4F-α-PVP); apex triggering, 3–6 s; dynamic exclusion, 2 s; AGC target, 1 × 105 ;
max IT, 50 ms. Inclusion lists were generated based on prior metabolite identification
studies [21–23,49] and postulation (Table 2).
Table 2. Inclusion and neutral loss lists for the FullMS/ddMS2 and FullMS/AIF/ddMS2 acquisitions, respectively, used
during HRMS analysis of hepatocytes incubations. FullMS/ddMS2, full-scan mass spectrometry/data-dependent tandem
mass spectrometry; FullMS/AIF/ddMS2, full-scan mass spectrometry/all-ion fragmentation/data-dependent tandem mass
spectrometry; HRMS, high resolution mass spectrometry.
α-PHP.
FullMS/ddMS2 acquisition
[M + H]+ (m/z)
Formula
192.1383
C12 H17 NO
208.1332
C12 H17 NO2
244.1696
C16 H21 NO
246.1852
C16 H23 NO
248.2009
C16 H25 NO

[M + H]+ (m/z)
260.1645
262.1802
264.1958
276.1594
278.1751

Formula
C16 H21 NO2
C16 H23 NO2
C16 H25 NO2
C16 H21 NO3
C16 H23 NO3

[M + H]+ (m/z)
280.1907
292.1543
296.1856
342.1370
438.2122

Formula
C16 H25 NO3
C16 H21 NO4
C16 H25 NO4
C16 H23 NSO5
C22 H31 NO8

FullMS/AIF/ddMS2 acquisition
Neutral loss (m/z)
Fragment loss
−57.0704
−C4 H9
−71.0735
−C4 H9 N
−79.9563
−SO3
−106.0418
−C7 H6 O

Neutral loss (m/z)
−127.1361
−141.1517
−155.1310
−162.1044

Fragment loss
−C8 H17 N
−C9 H19 N
−C9 H17 NO
−C11 H14 O

Neutral loss (m/z)
−174.1044
−176.1201
−176.0315

Fragment loss
−C12 H14 O
−C12 H16 O
−C6 H8 O6

[M + H]+ (m/z)
252.1758
262.1438
264.1394
264.1594
266.1551
268.1707
278.1387
280.1344
282.1500

Formula
C15 H22 FNO
C15 H19 NO3
C15 H18 FNO2
C15 H21 NO3
C15 H20 FNO2
C15 H22 FNO2
C15 H19 NO4
C15 H18 FNO3
C15 H20 FNO3

[M + H]+ (m/z)
282.1700
284.1657
296.1293
300.1606
328.1213
346.1119
424.1966
442.1872

Formula
C15 H23 NO4
C15 H22 FNO3
C15 H18 FNO4
C15 H22 FNO4
C15 H21 NSO5
C15 H20 FNSO5
C21 H29 NO8
C21 H28 FNO8

4F-α-PVP
FullMS/ddMS2 acquisition
[M + H]+ (m/z)
Formula
194.1176
C11 H15 NO2
196.1132
C11 H14 FNO
212.1081
C11 H14 FNO2
232.1696
C15 H21 NO
246.1489
C15 H19 NO2
248.1445
C15 H18 FNO
248.1645
C15 H21 NO2
250.1602
C15 H20 FNO
250.1802
C15 H23 NO2
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Table 2. Cont.
FullMS/AIF/ddMS2 acquisition
Neutral loss (m/z)
Fragment loss
−43.0548
−C3 H7
−71.0735
−C4 H9 N
−79.9563
−SO3
−113.1205
−C7 H15 N

Neutral loss (m/z)
−124.0325
−127.1361
−141.1154
−166.0794

Fragment loss
−C7 H5 FO
−C8 H17 N
−C8 H15 NO
−C10 H11 FO

Neutral loss (m/z)
−176.0315
−178.0794
−180.0951

Fragment loss
−C6 H8 O6
−C11 H11 FO
−C11 H13 FO

Bold indicates parent drugs.

In a second injection, data were acquired in FullMS/all-ion fragmentation (AIF)/ddMS2
mode, which triggered MS/MS data acquisitions based on specific neutral losses detected
in FullMS and AIF scans. FullMS and ddMS2 settings were the same as described above.
Resolution, intensity threshold, mass range, NCE, AGC target, and max IT were the same
as those of ddMS2 . Neutral loss lists were generated based on the fragmentation pattern
of parent drugs, i.e., α-PHP or 4F-α-PVP, in the conditions of the analysis, and including
glucuronide and sulfate losses in case of phase II metabolism (Table 2).
3.5. Metabolite Identification
Raw data files from 0 and 3 h incubations and controls were processed with Compound
Discoverer™ (Thermo Scientific; Ancona, Italy) and compiled in a single analysis. Retention
times of the chromatographic peaks were aligned following an adaptive curve model
with a 5-ppm mass tolerance and a 0.1-min maximum time shift. Mass tolerance for MS
identification was 5 ppm, with a 13,000 intensity threshold (20,000 for 4F-α-PVP) and a 50%
intensity tolerance for isotopes. Mass tolerance for fragment identification was 10 ppm,
with a signal-to-noise ratio higher than 3. Chromatographic peaks detected in controls
with a similar or higher intensity than α-PHP and 4F-α-PVP incubations were filtered out.
Detected peaks were compared to a list of theoretical molecules automatically generated
by a combination of probable metabolic transformations, following the settings displayed
in Table 3.
Table 3. Compound Discoverer™ processing settings for identifying α-PHP and 4F-α-PVP metabolites.
α-PHP

4F-α-PVP

Phase I expected transformations

Dehydrogenation (–2H), dihydrodiol
formation (+2O +2H), oxidation (+O),
oxidative deamination to alcohol (–N +O
–H), oxidative deamination to ketone (–N
+O –3H), reduction (+2H)

Dehydrogenation (–2H), dihydrodiol
formation (+2O +2H), oxidation (+O),
oxidative deamination to alcohol (–N +O
–H), oxidative deamination to ketone (–N
+O –3H), oxidative defluorination (–F +O
+H), reduction (+2H), reductive
defluorination (–F +H)

Phase II expected transformations

Acetylation (+2C +O +2H),
glucuronidation (+6C +6O +10H),
sulfation (+S +3O)

Acetylation (+2C +O +2H),
glucuronidation (+6C +6O +10H),
sulfation (+S +3O)

Maximum number of dealkylation steps

2

2

Maximum number of phase II reactions

1

1

Maximum number of reactions

5

5

4. Conclusions
We have provided the first metabolic profile of 4F-α-PVP and identified an additional
major metabolite of α-PHP using human hepatocyte incubations, LC-HRMS/MS analysis,
and data-mining software. We suggest α-PHP dihydroxy-pyrrolidinyl (P2), α-PHP hexanol
(P3), α-PHP 20 -keto-pyrrolidinyl-hexanol (P4), and α-PHP d20 -keto-pyrrolidinyl (P5) as
markers of α-PHP use, and 4F-α-PVP dihydroxy-pyrrolidinyl (F2), 4F-α-PVP hexanol (F3),
4F-α-PVP 20 -keto-pyrrolidinyl-hexanol (F4), and 4F-α-PVP d20 -keto-pyrrolidinyl (F5) as
markers of 4F-α-PVP use. The identification of this new α-PHP metabolite (P2) may be
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critical to prove α-PHP use in clinical or forensic settings and to further substantiate findings from hepatic microsome investigations. These results must be confirmed with further
experiments using suitable reference standards. Additionally, these are also valuable data
for standard manufacturers to focus their synthesis efforts. Further pharmacokinetic and
pharmacodynamic studies should be performed to better understand the effects of α-PHP
and 4F-α-PVP.
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3”,4”-Methylenedioxy-α-pyrrolidinohexiophenone
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World Health Organization
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